ASH 2023
Important data on transplant-eligible NDMM
Perseus, Iskia
ASH 2023
Important data on transplant-eligible NDMM
SWOG S0777/S1211, EMN20, Rest
ASH 2023
Update on transplant-ineligible NDMM
IsKia
ASH 2023
CD38 antibodies - good in 1st line but bad in 2nd line?
Perseus, IsKia, IFM 2018-04
ASH 2023
Quatruplet therapy - the new standard in induction &…
IsKia
ASH 2023
Isa-KRd - practice changing?
Perseus
ASH 2023
Practice changing - Daratumumab before und after…
Perseus
ASH 2023
Daratumumab vor und nach Transplantation neuer Standard
Perseus, IsKia, IFM 2018-04
ASH 2023
Vierfachkombinationen - der neue Standard bei Induktion…
IsKia
ASH 2023
CD38-antistoffer - bra i førstelinje men ikke i…
IsKia
ASH 2023
Isa-KRd - practice changing?
KarMMa-3
ASH 2023
The future of CAR T Cell treatment - I
CARTITUDE-2
ASH 2023
The future of CAR T Cell treatment - II
MonumenTAL-1
ASH 2023
Bispecific antibodies - update and outlook on treatment…
ASH 2023
Single-cell analysis of CAR T cells
ASH 2023
Early data on TriTac
CARTITUDE-2
ASH 2023
cilta-cel in early lines
ASH 2023
Response predictors in immunotherapy
KarMMa-3
ASH 2023
Survival data from KarMMa-3
ASH 2023
New data on efficacy and safety of CAR T cells and…
ASH 2023
Einzelzell-Analysen bei CAR-T-Zellen
ASH 2023
CAR-T-Zellen und bispezifische Antikörper/TCEs: Neue…
CARTITUDE-2
ASH 2023
cilta-cel in frühen Linien
KarMMa-3
ASH 2023
Overlevelsesdata fra KarMMa-3
Istopmm
ASH 2023
Are we ready for screening?
Immuno-PRISM
ASH 2023
Are we preventing myeloma yet?
CENTAURUS
ASH 2023
CENTAURUS: using single-drug Daratumumab in smoldering…
ASH 2023
First whole genome sequencing trial with long-term FUP…
CENTAURUS
ASH 2023
CENTAURUS: using single-drug Daratumumab in smoldering…
ASH 2023
First whole genome sequencing trial with long-term FUP…
ELARA, CO41942, LYSA
ASH 2023
Updates for immunotherapy of follicular lymphoma
ASH 2023
Bispecific antibodies in follicular lymphoma (1st line)
TRANSCEND FL
ASH 2023
CAR T cells in follicular lymphoma (1st relapse)
ASH 2023
Chemo-free combination for 1st line follicular lymphoma
ELARA
ASH 2023
Long-term follow-up of ELARA study
Descart Registry Analysis from Lysa
ASH 2023
Real-world data of CAR T in relapsed follicular…
ASH 2023
Cost-effectiveness analysis of Mosunetuzumab and CAR T…
ASH 2023
Bispezifische Antikörper im follikulären Lymphom (1st…
ASH 2023
Analisi costo-beneficio di mosunetuzumab vs CART nel…
Descart Registry Analysis from Lysa
ASH 2023
Data "real world" delle CART nel linfoma follicolare…
ELARA
ASH 2023
Follow-up a lungo termine dello studio ELARA
ASH 2023
Una combinazione chemo-free per la prima linea del…
TRANSCEND FL
ASH 2023
CAR-T-Zellen im follikulären Lymphom (erstes Rezidiv)
Ilyad
ASH 2023
No efficacy of vitamin D in rituximab therapy
Ilyad
ASH 2023
Keine Wirksamkeit von Vitamin D bei Rituximab-Therapie
ASH 2023
New data for MCL - part I
Lyma and Lyma-101 comparison, Sympatico
ASH 2023
New data for MCL - part II
SYMPATICO
ASH 2023
Ibrutinib plus Venetoclax in R/R MCL - a new treatment…
Sympatico
ASH 2023
A new standard for R/R MCL?
ASH 2023
Sequential use of R-bendamustine and ibrutinib?
Lyma and Lyma-101 comparison
ASH 2023
Is obinutuzumab superior to rituximab in MCL?
ASH 2023
Adding Ara-C and lenalidomide to the standard RCHOP+RM…
ASH 2023
Venetoclax added to RBAC significantly improves PFS in…
SYMPATICO
ASH 2023
The SYMPATICO study confirms the synergy between…
ASH 2023
TP53-mutant MCL - a new standard in 1st line?
ASH 2023
Sobering results for bendamustine and venotoclax in MCL…
ASH 2023
BOVEN: An effective MRD-guided strategy free of chemo…
ASH 2023
Añadir Ara-C y lenalidomida al estándar RCHOP+MR no…
ASH 2023
BOVEN: Una estrategia sin quimio guiada por EMR,…
ASH 2023
Ernüchternde Ergebnisse für Bendamustin und Venotoclax…
ASH 2023
Venetoclax mejora significativamente la PFS de RBAC en…
Lyma and Lyma-101 comparison
ASH 2023
Vilken CD20-antikropp är att föredra vid MCL?
ASH 2023
MCL mit TP53-Mutation: Neuer Standard in der Erstlinie?
SYMPATICO
ASH 2023
Ibrutinib plus Venetoclax beim rezidivierenden MCL -…
SYMPATICO
ASH 2023
El estudio SYMPATICO confirma la sinergia entre…
ASH 2023
Sekventiell eller samtidig behandling med R-bendamustin…
Sympatico
ASH 2023
Ny standardbehandling för recidiv av MCL?
GAIA/CLL13, FLAIR, ALPINE, ELEVATE-TN
ASH 2023
Highlights in chronic lymphocytic leukemia
BRUIN
ASH 2023
Pirtobrutinib in relapsed CLL
FLAIR
ASH 2023
Ibrutinib plus venetoclax as MRD-guided treatment
ASH 2023
Sonrotoclax plus zanubrutinib in 1st line CLL
ASH 2023
Bv-AVD in older patients
ASH 2023
Nivo-AVD bei älteren Patienten besser als Bv-AVD
ASH 2023
DLBCL - new treatment approaches and diagnostic…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!